J Inflamm Res. 2026 Nov 17;19:540837. doi: 10.2147/JIR.S540837. eCollection 2026.
ABSTRACT
Disease modification (DM), a concept originating in rheumatology, has recently emerged as a therapeutic goal in dermatology, shifting the management of chronic inflammatory skin diseases away from a traditional "control-and-clear" approach toward altering the long-term disease course. However, no unified definition exists, and its meaning necessarily varies with disease biology. This narrative review, based on a structured literature search following SANRA guidance, appraises DM across seven cutaneous immune-mediated inflammatory diseases (IMIDs)-atopic dermatitis, vitiligo, hidradenitis suppurativa, alopecia areata, autoimmune bullous diseases, chronic spontaneous urticaria, and psoriasis-using explicit criteria and a uniform evidence-grading scale. In conditions causing irreversible structural damage-dermal tunnels and fibrosis in hidradenitis suppurativa, progression to psoriatic arthritis, and scarring in bullous diseases-DM aims chiefly to prevent cumulative tissue injury through early, sustained inflammatory control. In diseases without permanent damage, it is better defined by sustained treatment-free remission, relapse prevention, and restoration of immune homeostasis. Rituximab in pemphigus vulgaris is currently the only therapy convincingly fulfilling stringent DM criteria, through durable treatment-free remission and immune remodeling. Psoriasis represents the most advanced model, with IL-23p19 inhibition showing the most consistent evidence and IL-17 inhibition showing emerging signals; dupilumab offers the strongest support in atopic dermatitis, IL-17 inhibition provides the most robust disease control in hidradenitis suppurativa, without demonstrated treatment-free remission, whereas JAK inhibitors in vitiligo and alopecia areata remain disease-controlling. A recurring theme is the therapeutic window of opportunity, which remains a hypothesis, as no trial has randomized early versus delayed initiation of the same therapy. Persistent tissue-resident memory T cells, insufficient regulatory control, and residual molecular scars remain key barriers. We propose minimum trial-design features-randomized withdrawal, off-treatment endpoints, paired tissue sampling, and long-term follow-up-to demonstrate DM.
PMID:43068149 | PMC:PMC13788819 | DOI:10.2147/JIR.S540837